vs

Side-by-side financial comparison of Cellectis S.A. (CLLS) and ECB Bancorp, Inc. (ECBK). Click either name above to swap in a different company.

ECB Bancorp, Inc. is the larger business by last-quarter revenue ($9.5M vs $9.5M, roughly 1.0× Cellectis S.A.). ECB Bancorp, Inc. runs the higher net margin — 27.3% vs -265.9%, a 293.2% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs 33.8%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $9.0M).

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.

CLLS vs ECBK — Head-to-Head

Bigger by revenue
ECBK
ECBK
1.0× larger
ECBK
$9.5M
$9.5M
CLLS
Growing faster (revenue YoY)
CLLS
CLLS
+341.1% gap
CLLS
375.0%
33.8%
ECBK
Higher net margin
ECBK
ECBK
293.2% more per $
ECBK
27.3%
-265.9%
CLLS
More free cash flow
CLLS
CLLS
$18.6M more FCF
CLLS
$27.6M
$9.0M
ECBK

Income Statement — Q2 FY2024 vs Q4 FY2025

Metric
CLLS
CLLS
ECBK
ECBK
Revenue
$9.5M
$9.5M
Net Profit
$-25.3M
$2.6M
Gross Margin
Operating Margin
-181.1%
36.7%
Net Margin
-265.9%
27.3%
Revenue YoY
375.0%
33.8%
Net Profit YoY
-51.9%
79.5%
EPS (diluted)
$-0.28
$0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLLS
CLLS
ECBK
ECBK
Q4 25
$9.5M
Q3 25
$8.8M
Q2 25
$8.0M
Q1 25
$6.9M
Q4 24
$7.1M
Q3 24
$6.6M
Q2 24
$9.5M
$6.3M
Q1 24
$6.2M
Net Profit
CLLS
CLLS
ECBK
ECBK
Q4 25
$2.6M
Q3 25
$2.4M
Q2 25
$1.4M
Q1 25
$1.3M
Q4 24
$1.4M
Q3 24
$1.1M
Q2 24
$-25.3M
$791.0K
Q1 24
$621.0K
Operating Margin
CLLS
CLLS
ECBK
ECBK
Q4 25
36.7%
Q3 25
37.0%
Q2 25
23.9%
Q1 25
24.9%
Q4 24
27.3%
Q3 24
23.3%
Q2 24
-181.1%
16.9%
Q1 24
13.4%
Net Margin
CLLS
CLLS
ECBK
ECBK
Q4 25
27.3%
Q3 25
27.7%
Q2 25
18.0%
Q1 25
18.7%
Q4 24
20.3%
Q3 24
17.2%
Q2 24
-265.9%
12.6%
Q1 24
10.0%
EPS (diluted)
CLLS
CLLS
ECBK
ECBK
Q4 25
$0.32
Q3 25
$0.29
Q2 25
$0.17
Q1 25
$0.16
Q4 24
$0.18
Q3 24
$0.14
Q2 24
$-0.28
$0.09
Q1 24
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLLS
CLLS
ECBK
ECBK
Cash + ST InvestmentsLiquidity on hand
$149.0M
$82.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$148.6M
$171.9M
Total Assets
$407.1M
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLLS
CLLS
ECBK
ECBK
Q4 25
$82.8M
Q3 25
$201.9M
Q2 25
$191.0M
Q1 25
$143.7M
Q4 24
$309.4M
Q3 24
$114.8M
Q2 24
$149.0M
$108.7M
Q1 24
$109.8M
Stockholders' Equity
CLLS
CLLS
ECBK
ECBK
Q4 25
$171.9M
Q3 25
$169.3M
Q2 25
$168.3M
Q1 25
$168.6M
Q4 24
$168.3M
Q3 24
$166.0M
Q2 24
$148.6M
$166.5M
Q1 24
$165.8M
Total Assets
CLLS
CLLS
ECBK
ECBK
Q4 25
$1.6B
Q3 25
$1.6B
Q2 25
$1.5B
Q1 25
$1.5B
Q4 24
$1.4B
Q3 24
$1.4B
Q2 24
$407.1M
$1.3B
Q1 24
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLLS
CLLS
ECBK
ECBK
Operating Cash FlowLast quarter
$28.9M
$9.2M
Free Cash FlowOCF − Capex
$27.6M
$9.0M
FCF MarginFCF / Revenue
290.5%
94.7%
Capex IntensityCapex / Revenue
13.2%
2.2%
Cash ConversionOCF / Net Profit
3.55×
TTM Free Cash FlowTrailing 4 quarters
$14.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLLS
CLLS
ECBK
ECBK
Q4 25
$9.2M
Q3 25
$4.0M
Q2 25
$1.9M
Q1 25
$-631.0K
Q4 24
$6.2M
Q3 24
$861.0K
Q2 24
$28.9M
$1.4M
Q1 24
$-429.0K
Free Cash Flow
CLLS
CLLS
ECBK
ECBK
Q4 25
$9.0M
Q3 25
$4.0M
Q2 25
$1.8M
Q1 25
$-649.0K
Q4 24
$6.2M
Q3 24
Q2 24
$27.6M
$1.3M
Q1 24
$-449.0K
FCF Margin
CLLS
CLLS
ECBK
ECBK
Q4 25
94.7%
Q3 25
44.9%
Q2 25
23.0%
Q1 25
-9.4%
Q4 24
86.8%
Q3 24
Q2 24
290.5%
21.4%
Q1 24
-7.2%
Capex Intensity
CLLS
CLLS
ECBK
ECBK
Q4 25
2.2%
Q3 25
0.8%
Q2 25
0.6%
Q1 25
0.3%
Q4 24
0.8%
Q3 24
0.0%
Q2 24
13.2%
0.6%
Q1 24
0.3%
Cash Conversion
CLLS
CLLS
ECBK
ECBK
Q4 25
3.55×
Q3 25
1.65×
Q2 25
1.32×
Q1 25
-0.49×
Q4 24
4.31×
Q3 24
0.76×
Q2 24
1.75×
Q1 24
-0.69×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons